What are the nerve‑involving forms of leprosy (Hansen disease) and their respective treatments?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nerve-Involving Forms of Leprosy and Their Treatments

Leprosy affects peripheral nerves across a clinical spectrum determined by the host's immune response, with treatment centered on multidrug therapy (MDT) using dapsone, rifampicin, and clofazimine, while corticosteroids are essential for managing acute neuritis and preventing irreversible nerve damage.

Clinical Classification of Nerve-Involving Leprosy

The nerve manifestations of leprosy follow the Ridley-Jopling classification spectrum, which directly correlates with the degree of cell-mediated immunity 1:

Tuberculoid Leprosy (TT) and Borderline Tuberculoid (BT)

  • Pattern: Asymmetric, multifocal nerve involvement
  • Mechanism: Strong cell-mediated immune response creates granulomas that destroy bacilli but also damages neighboring nerve fibers
  • Clinical features: Few, well-demarcated hypopigmented skin lesions with marked sensory loss; peripheral nerve thickening in specific distributions
  • Nerve pathology: Predominantly demyelination with granuloma formation 1, 2

Lepromatous Leprosy (LL) and Borderline Lepromatous (BL)

  • Pattern: Symmetric, pseudo-polyneuritic distribution (mimics length-dependent polyneuropathy)
  • Mechanism: Weak immune response allows widespread bacillary invasion of Schwann cells, endothelial cells, and macrophages
  • Clinical features: Multiple bilateral skin lesions; diffuse peripheral nerve involvement
  • Nerve pathology: Bacilli easily demonstrated in nerve tissue; both demyelination (100%) and axonal damage (60%) present 2

Pure Neural Leprosy (PNL)

  • Pattern: Peripheral neuropathy without skin lesions (occurs in up to 10% of cases)
  • Diagnosis: Requires nerve biopsy for confirmation 1
  • Clinical challenge: Often presents to neurology departments with isolated neuropathy 2

Standard Treatment Regimens

Multidrug Therapy (MDT) - Primary Treatment 3, 1

Paucibacillary (PB) Leprosy (TT, BT):

  • Duration: 6 months
  • Regimen: Dapsone + Rifampicin

Multibacillary (MB) Leprosy (BB, BL, LL):

  • Duration: 12 months
  • Regimen: Dapsone + Rifampicin + Clofazimine
  • Dosing for clofazimine: 2-3 mg/kg/day (maximum 100 mg daily) 4
  • Monitoring: Monthly ECGs when using clofazimine, especially with other QTc-prolonging agents; counsel patients about reversible skin pigmentation 4

Critical Caveat on Nerve Damage

Peripheral nerve damage is irreversible once established 3. The window for preventing permanent disability closes rapidly, making early diagnosis and treatment paramount. Sensory loss persists despite successful bacterial eradication, leading to secondary trophic changes from repeated trauma in painless areas 1.

Management of Leprosy Reactions and Acute Neuritis

Type 1 Reactions (Reversal Reactions)

  • Mechanism: Sudden increase in cell-mediated immunity in borderline cases
  • Nerve impact: Acute neuritis with rapid nerve deterioration
  • Treatment: Corticosteroids are the primary intervention 5
    • Must be initiated immediately to prevent irreversible damage
    • Continue MDT concurrently—do not stop antimicrobial therapy 3
    • Success is limited if nerve function impairment already present at diagnosis 5

Type 2 Reactions (Erythema Nodosum Leprosum)

  • Occurs in: Lepromatous and borderline lepromatous cases
  • Treatment: Corticosteroids plus continuation of MDT 3

Subclinical Neuropathy

  • Detection: Nerve conduction studies can identify subclinical involvement 3
  • Treatment: Corticosteroids even in absence of clinical symptoms to prevent progression 5

Symptomatic Management of Neuropathic Pain

First-line agents 3:

  • Pregabalin
  • Amitriptyline

These address the neuropathic pain component that occurs despite the characteristic sensory loss of leprosy 5.

Diagnostic Algorithm for Nerve Involvement

When evaluating suspected leprosy neuropathy 2:

  1. Clinical assessment: Look for asymmetric nerve thickening, sensory loss in specific nerve distributions, limb numbness (100% of cases), decreased muscle strength (90%), skin lesions (82%)

  2. Nerve ultrasonography: Identifies peripheral nerve asymmetry and segmental thickening (100% sensitivity in confirmed cases)

  3. Electrodiagnostic studies: Sensory nerve non-response occurs more frequently than motor nerve involvement (51% vs 25%, p=0.018)

  4. Confirmatory testing:

    • Molecular testing (PCR): 100% positive in confirmed cases
    • Skin/nerve biopsy with acid-fast staining: 54-100% positive
    • Serology: Only 36% positive

The combination of nerve ultrasound, electrodiagnostic studies, nerve biopsy, and molecular testing provides optimal diagnostic accuracy 2.

Rehabilitation and Long-term Management

Beyond antimicrobial and anti-inflammatory treatment 3:

  • Physical therapy for muscle atrophy
  • Orthoses and prostheses for finger/toe deformities and limb deficiencies
  • Collaboration between dermatologists and physiatrists is essential for comprehensive care

Key Clinical Pitfall

The most common error is delaying corticosteroid therapy in acute neuritis. Nerve damage progresses rapidly during reactions, and corticosteroids must be started immediately while continuing MDT 3, 5. Waiting for complete diagnostic confirmation before initiating corticosteroids risks permanent disability, as nerve function impairment present at treatment initiation predicts poor outcomes.

References

Research

Leprous neuropathy.

Handbook of clinical neurology, 2013

Research

[Hansen's Disease].

Brain and nerve = Shinkei kenkyu no shinpo, 2026

Guideline

new and repurposed drugs for pediatric multidrug-resistant tuberculosis. practice-based recommendations.

American Journal of Respiratory and Critical Care Medicine, 2017

Research

Treatment and Evaluation Advances in Leprosy Neuropathy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.